Business ❯ Pharmaceutical Industry

Clinical Research

Drug Development Regulatory Affairs Trial Results Drug Approval Innovation Drug Approval Process Innovative Treatments Market Competition Product Launch Partnerships Collaboration Agreements Funding Novo Nordisk Market Impact Stock Market AstraZeneca Collaboration

AI-Designed Drug Rentosertib Lowers Biological-Age Signals in Small Trial

The results could point to a druggable way to alter biological aging if larger trials confirm the biomarker changes.

EyePoint Stock Collapses After Duravyu Misses Phase 3 Primary Endpoint

Purified THC‑CBD Drug Cuts Agitation in End‑of‑Life Dementia, Trial Shows

Avalo Therapeutics Reports Positive Phase 2 HS Results, Prices $375 Million Offering

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Belite Bio’s Tinlarebant Cuts Stargardt Lesion Growth 36% in Phase 3 Trial

AstraZeneca’s Baxdrostat Lowers 24-Hour Systolic BP by 14 mmHg in Phase 3, AHA Presentation Confirms

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

Harvard Team Releases PDGrapher, an AI to Predict Gene and Drug Combos That Reverse Diseased Cell States

Jaypirca Delivers Significant PFS Benefit Over Chemoimmunotherapy in First-Line CLL/SLL

Arvinas’ Vepdegestrant Delays Breast Cancer Progression Longer Than Faslodex